Key Points
-
Driving under the influence of cannabis has been identified as a public health concern as medical and recreational cannabis availability increases in some countries.
-
A recent randomized clinical trial found similar levels of acute driving impairment with THC-dominant cannabis and with a combination of THC-CBD equivalent cannabis using on-road driving tests that provided real-world conditions; however, CBD-dominant cannabis did not produce significant cognitive or psychomotor impairment compared with placebo in this trial.
-
Media coverage of this study conveyed the findings as CBD-dominant cannabis not causing driving impairment while THC-dominant cannabis does, with the latter lasting up to 4 h post-dose.
-
It is recommended that clinicians counsel about the risks of driving impairment when patients disclose use of cannabis products containing THC.
